| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Flavonoids — a large class of plant polyphenols (natural products) including flavonols (quercetin, kaempferol), flavones (apigenin, luteolin), flavanones (naringenin), isoflavones (genistein), flavan-3-ols (EGCG/catechins), and anthocyanins. Sources: fruits/berries, tea/cocoa, legumes, herbs, and standardized extracts. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Many flavonoids have low oral bioavailability (rapid phase II conjugation: glucuronidation/sulfation; microbiome-derived metabolites). Plasma free aglycone levels are typically low; tissue effects often reflect metabolites and chronic exposure. In-vitro vs oral exposure: Many “anti-cancer” cytotoxic effects occur at micromolar aglycone concentrations exceeding typical systemic exposure from diet/supplements (high concentration only), unless specialized formulations or local GI exposure is the intent. Clinical evidence status: Broad epidemiology + small human trials for cardiometabolic/inflammatory endpoints; oncology evidence mostly preclinical/adjunct-hypothesis; no class-wide RCT oncology approval. Flavonoids are classified into seven structural classes: 1.flavanones -Nargenin, Naringin, Hesperetin, Isosakuranetin, Eriodictyol, Taxifolin 2.flavonols -Quercetin, Myrcetin, Fisetin, Rutin Morin, Kaempferol 3.chalcones -Butein, Xanthohumol, Isoliquintigenin, Cardamonin, Bavachalone, Xanthohumol, Phloretin 4.flavanols -Catechin, Gallocatechin, Epicatechin, Epigallocatechin-3-galate 5.anthocyanidins -Cyanidin 6.flavones -Chrysin, Apigenin, Luteolin, Vitexin, Orientin, Bacalein, Wogonin, Oroxylin A, Saponarin 7.isoflavonoids -Daidzein, Genistein, Glycitein Flavonoids — Cancer vs Normal Cell Pathway Map (Class-Level)
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Flavonoids — AD relevance: Flavonoid-rich diets and select supplements are studied for neuroprotection via antioxidant/anti-inflammatory effects, cerebrovascular support, and synaptic plasticity signaling. Effects are generally supportive and exposure/metabolite dependent. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Brain effects likely mediated by metabolites and chronic intake; large variability by subclass and microbiome. Clinical evidence status: Signals in small human trials (often with specific subclasses like cocoa flavanols/anthocyanins); AD disease-modification not established. Flavonoids — AD / Neurodegeneration Pathway Map (Class-Level)
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| PKM2/PKM1 ratio -PKM (pyruvate kinase M) exists mainly as two splice isoforms: PKM1 and PKM2. -PKM1 is constitutively active and typically found in tissues with high-energy demands (e.g., muscle, brain). -PKM2 is less active under some conditions and is highly regulated; importantly, it is often upregulated in cancers. - A higher PKM2/PKM1 ratio is thought to promote the “Warburg effect” (aerobic glycolysis) that benefits rapidly proliferating tumor cells by providing biosynthetic precursors even though it is less energy efficient. -An increased PKM2/PKM1 ratio has been associated with enhanced tumor cell proliferation, survival, and metastasis. |
| 2313- | Flav, | Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:227 Target#:1291 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid